摘要
目的本次研究对阿托伐他汀联合曲美他嗪治疗冠心病的疗效加以探讨。方法抽取2017年7月—2019年10月在医院住院治疗的90例冠心病患者为对象,采用随机数字表法将入选患者分为两组,每组各45例,其中一组成员纳入对照组单纯采用阿托伐他汀治疗,另外一组成员纳入观察组联合曲美他嗪治疗,对比两组取得的疗效、血脂水平、血液流变学指标及安全性。结果与对照组82.22%的疾病控制率相比,观察组97.78%的疾病控制率显著更高(P<0.05);治疗后,两组患者的血脂水平均得以改善,与对照组比较,观察组TG、TC及LDL-C水平下降幅度更大,HDL-C水平上升幅度更大(P<0.05);治疗后,两组患者的血液流变学均得以下降,与对照组比较,观察组下降幅度显著更大(P<0.05);观察组失眠1例、恶心呕吐2例及腹胀2例,不良反应率11.11%(5/45),对照组失眠1例、恶心呕吐2例及腹胀1例,不良反应率8.89%(4/45),两组对比,差异无统计学意义(P>0.05)。结论针对冠心病患者,采用阿托伐他汀联合曲美他嗪对于疾病的控制有着积极作用,改善患者血脂水平及血液流变学水平,且未见不良反应增加,安全性良好。
Objective To investigate the efficacy of atorvastatin combined with trimetazidine in the treatment of coronary heart disease.Methods From July 2017 to October 2019 in our hospital 90 cases hospitalized patients with coronary heart disease(CHD)as the object,using the random number table method selected patients divided into two groups,each group 45 cases each,one group included in the control group only with atorvastatin treatment,the other group members into the observation group with trimetazidine therapy,compared two groups of curative effect,blood lipid levels and blood rheology indexes and security.Results Compared with 82.22%of the control group,97.78%of the observation group had a significantly higher control rate(P<0.05).After treatment,the serum lipid levels of patients in both groups were improved.Compared with the control group,the TG,TC and ldl-c levels in the observation group decreased more,while the hdl-c level increased more(P<0.05).After treatment,hemorheology of patients in both groups decreased,and the decrease was significantly greater in the observation group than in the control group(P<0.05).In the observation group,there was 1 case of insomnia,2 cases of nausea and vomiting and 2 cases of abdominal distension,with an adverse reaction rate of 11.11%(5/45);in the control group,there was 1 case of insomnia,2 cases of nausea and vomiting and 1 case of abdominal distension,with an adverse reaction rate of 8.89%(4/45),with no significant difference between the two groups(P>0.05).Conclusion For patients with coronary heart disease,the use of atorvastatin combined with trimetazidine has a positive effect on the control of the disease,improving the level of blood lipid and hemorheology,and no increase in adverse reactions and good safety.
作者
李亚洲
刘园
LI Yazhou;LIU Yuan(Department of Cardiology,Xiaogan First People’s Hospital,Xiaogan Hubei 432000,China;Department of General Medicine,Xiaogan First People’s Hospital,Xiaogan Hubei 432000,China)
出处
《中国继续医学教育》
2020年第34期136-140,共5页
China Continuing Medical Education
关键词
阿托伐他汀
曲美他嗪
冠心病
疗效
血脂水平
血液流变学指标
安全性
atorvastatin
trimetazidine
coronary heart disease(CHD)
curative effect
blood lipid level
hemorheology index
security
